Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group

Gynecologic Oncology

Volumn 123, Issue 3, 2011, Pages 499-504

  Ramasubbaiah, R ^a   Perkins, S M ^a   Schilder, J ^a   Whalen, C ^b   Johnson, C S ^a   Callahan, M ^c   Jones, T ^d   Sutton, G ^c   Matei, D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fort Wayne Medical Oncology and Hematology   (United States)

^c St Vincent Hospitals and Health Services   (United States)

^d Clarian Arnett   (United States)

Author keywords

Clinical trial; Ovarian cancer; Phase I II; Platinum resistant; Sorafenib; Topotecan

Indexed keywords

PLATINUM; SORAFENIB; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INSOMNIA; LEUKOPENIA; LIVER FUNCTION; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PYRIDINES; TOPOTECAN;

EID: 81155148279     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.033     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin. 60 5 2010 Sep-Oct 277 300
2. M.R.L. Horner, and M. Krapcho SEER Cancer Statistics Review, 1975-2006 2009 National Cancer Institute Bethesda, MD
3. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 14 2001 Jul 15 3312 3322 (Pubitemid 32642183)
4. H.D. Homesley, D.J. Hall, D.A. Martin, G.S. Lewandowski, L. Vaccarello, and W.A. Nahhas A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients Gynecol Oncol 83 2 2001 Nov 394 399 (Pubitemid 33033085)
5. R. Morris, R.D. Alvarez, S. Andrews, J. Malone, C. Bryant, and L.K. Heilbrun Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers Gynecol Oncol 109 3 2008 Jun 346 352
6. T. Levy, M. Inbar, J. Menczer, D. Grisaru, M. Glezerman, and T. Safra Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer Gynecol Oncol 95 3 2004 Dec 686 690 (Pubitemid 39592538)
7. T. Safra, J. Menczer, R. Bernstein, S. Shpigel, M.J. Inbar, and D. Grisaru Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer Gynecol Oncol 105 1 2007 Apr 205 210 (Pubitemid 46441462)
8. A. Bonni, A. Brunet, A.E. West, S.R. Datta, M.A. Takasu, and M.E. Greenberg Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 5443 1999 Nov 12 1358 1362
9. R. Newbold Cancer: mutant ras proteins and cell transformation Nature 310 5979 1984 Aug 23-29 628 629
10. A.M. Chan, T. Miki, K.A. Meyers, and S.A. Aaronson A human oncogene of the RAS superfamily unmasked by expression cDNA cloning Proc Natl Acad Sci USA 91 16 1994 Aug 2 7558 7562 (Pubitemid 24238224)
11. C.H. Chien, and S.N. Chow Point mutation of the ras oncogene in human ovarian cancer DNA Cell Biol 12 7 1993 Sep 623 627
12. D. Matei, D.D. Chang, and M.H. Jeng Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation Clin Cancer Res 10 2 2004 Jan 15 681 690 (Pubitemid 38174008)
13. R. Henriksen, K. Funa, E. Wilander, T. Backstrom, M. Ridderheim, and K. Oberg Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms Cancer Res 53 19 1993 Oct 1 4550 4554 (Pubitemid 23304378)
14. S. Wilhelm, and D.S. Chien BAY 43-9006: preclinical data Curr Pharm Des 8 25 2002 2255 2257 (Pubitemid 35189898)
15. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011 Jan 1;29(1):69-75.
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 Feb 2 205 216
17. G.J. Hather, and H. Mackey Some notable properties of the standard oncology Phase I design J Biopharm Stat 19 3 2009 543 555
18. M.J. Duffy, J.M. Bonfrer, J. Kulpa, G.J. Rustin, G. Soletormos, and G.C. Torre CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Int J Gynecol Cancer 15 5 2005 Sep-Oct 679 691 (Pubitemid 41783071)
19. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011 Jan 10;29(2):242-8.
20. J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A.G. Zeimet, H. Sommer, and P. Klare Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 26 19 2008 Jul 1 3176 3182
21. F. Joly, T. Petit, P. Pautier, E. Guardiola, F. Mayer, and A. Chevalier-Place Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study Gynecol Oncol 115 3 2009 Dec 382 388
22. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010 Jun;117(3):473-6.
23. T. Le, L. Hopkins, K.A. Baines, L. Rambout, and M. Fung-Kee-Fung Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer Int J Gynecol Cancer 18 3 2008 May-Jun 428 431 (Pubitemid 351668309)
24. F. Abushahin, D.K. Singh, J.R. Lurain, E.C. Grendys, A.W. Rademaker, and J.C. Schink Weekly topotecan for recurrent platinum resistant ovarian cancer Gynecol Oncol 108 1 2008 Jan 53 57 (Pubitemid 350299419)
25. P.G. Rose, C. Tian, and M.A. Bookman Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 117 2 2010 May 324 329
26. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010 Apr 10;28(11):1835-42.
27. S. Cascinu RB, A.F. Sobrero, R. Labianca, P. Bidoli, S. Siena, and D. Ferraris Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: a randomized phase II trial J Clin Oncol 28 15 s 2010 4066 suppl, abstract
28. Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical Phase III and beyond. Recent Results Cancer Res.180:137-63.
29. C. Ferrario HC, S. Oyewole-Eletu, C.L. Mihalcioiu, A. Langleben, W.H. Miller, and R. Aloyz Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer J Clin Oncol 28 15 s 2010 1093 abstract
30. J. Crown VD, E. Staroslawska, D.A. Yardley, N. Davidson, T.D. Bachelot, and V.R. Tassell Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) J Clin Oncol 28 18 s 2010 Abstract LBA1011